9-Fluorenol

Cat. No.: HY-W016388

CAS No.: 1689-64-1

Molecular Formula: $C_{13}H_{10}O$

Molecular Weight: 182.22

Target: Dopamine Receptor; Drug Metabolite

Pathway: GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (548.79 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	5.4879 mL	27.4394 mL	54.8787 mL
	5 mM	1.0976 mL	5.4879 mL	10.9757 mL
	10 mM	0.5488 mL	2.7439 mL	5.4879 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (13.72 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (13.72 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

9-Fluorenol (9-Hydroxyfluorene; compound 3) is a dopamine (DAT) inhibitor with IC_{50} value of 9 μM. 9-Fluorenol is a major metabolite of compound developed as a wake promoting agent. 9-Fluorenol shows wake promotion activity in vivo[1].

In Vivo

Pharmacokinetic parameters of 9-Fluorenol (100 mg/kg; i.p.) in rats[1]

	Plasma	Brain
C_{max} , ng/g	263	4384

t_{max} , h	2	0.8
AUC_{0-t} , ng h/g	1081	11639

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Dunn D, et al. Wake promoting agents: search for next generation modafinil, lessons learned: part III. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3751-3.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA